Compare SPPL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPPL | SCYX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 42.4M |
| IPO Year | 2022 | 2014 |
| Metric | SPPL | SCYX |
|---|---|---|
| Price | $3.10 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 226.9K | 83.6K |
| Earning Date | 04-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.57 |
| 52 Week High | $7.00 | $5.62 |
| Indicator | SPPL | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 40.94 |
| Support Level | $2.49 | $0.66 |
| Resistance Level | $3.54 | $5.10 |
| Average True Range (ATR) | 0.22 | 0.37 |
| MACD | -0.05 | -0.17 |
| Stochastic Oscillator | 6.94 | 1.91 |
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software (Facilities management software). The majority of its revenue is generated from the Robots segment. The company has expanded its operations into Australia /New Zealand and may also enter or expand in other geographic markets such as Canada, Hong Kong, Japan, the Middle East, the United Kingdom, Europe and the United States.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.